Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-3576

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-3576). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

Figure-1 (Valsartan Hctz Figure 1)
A line chart showing the percentage of subjects with systolic blood pressure (SBP) less than 140 mmHg plotted against baseline SBP levels (140 to 180 mmHg). Four treatment groups are compared: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The chart illustrates the efficacy differences in lowering SBP among these treatments.*
FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

Figure-2 (Valsartan Hctz Figure 2)
A line graph illustrating the percentage of patients achieving diastolic blood pressure under 90 mmHg (% DBP<90) plotted against baseline diastolic blood pressure (mmHg). The graph compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, showing their relative effectiveness across a range of baseline DBP values from 90 to 110 mmHg.*
FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

Figure-3 (Valsartan Hctz Figure 3)
A line chart showing the percentage of patients with systolic blood pressure under 130 mmHg plotted against baseline systolic blood pressure (mmHg). Four treatment groups are compared: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers on the graph.*
FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

Figure-4 (Valsartan Hctz Figure 4)
A line graph displaying the percentage of diastolic blood pressure (DBP) below 80 mmHg plotted against baseline DBP values ranging from 90 to 110 mmHg. The graph compares four groups: Valsartan and Hydrochlorothiazide (320/25 mg), Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, showing the effectiveness in lowering DBP relative to baseline measures.*
FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Valsartan-str (Valsartan Hctz Valsartan)
Chemical structure of the active ingredient Valsartan as shown in the image.*
FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)
Chemical structure diagram of the active ingredient Valsartan and Hydrochlorothiazide, illustrating its molecular bonds and functional groups.*
FDA Label Image

Label Image (Lbl500903576)

Label Image (Lbl500903576)
Packaging label for Valsartan and Hydrochlorothiazide 80 mg/12.5 mg film-coated tablets by A-S Medication Solutions. The label indicates the product is an oral prescription drug, with 90 tablets per bottle. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit to protect from moisture. The label also includes a dosage safe package insert and details about the distributor and manufacturer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.